C. De Wolf‐Peeters

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

P. Dupont, L. Mortelmans, G. Bormans, 2003, Blood.

t(1;19) without detectable E2A rearrangements in two t(14; 18)‐positive lymphoma/leukemia cases

C. Mecucci, M. Stul, G. Verhoef, 1994, Genes, chromosomes & cancer.

Gene rearrangements in T‐cell lymphoblastic lymphoma

H. Müller-Hermelink, B. Falini, E. Pilozzi, 1999, The Journal of pathology.

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

P. Dupont, L. Mortelmans, G. Verhoef, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases

Robert Vlietinck, Herman Van den Berghe, C. Mecucci, 1997, British journal of haematology.

Co‐expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma

H. Müller-Hermelink, S. Pileri, H. Stein, 1998, The Journal of pathology.

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

P. Dupont, L. Mortelmans, G. Bormans, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

P. Dupont, L. Mortelmans, S. Stroobants, 2001, British journal of haematology.

Gene rearrangements in T‐cell lymphoblastic lymphoma

B. Falini, E. Pilozzi, K. Gatter, 1999, The Journal of pathology.